Lupus: Open Access
Open Access

Consequences of Liver Cirrhosis and Causes

Kurt Rand^{* *}Correspondence: Kurt Rand, Department of Clinical Medicine, University of Oxford, England, United Kingdom, Email:

Author info »

Description

Liver cirrhosis and lupus are two medical conditions that can occasionally be linked due to their impact on the body's immune system and their potential for causing liver damage. However, it's important to note that these conditions have different causes, mechanisms, and treatment approaches. The interlink between liver cirrhosis and lupus, detailing their individual characteristics and the ways in which they can intersect.

Liver cirrhosis is a chronic liver disease characterized by the progressive and irreversible scarring of the liver tissue. This scarring, known as fibrosis, disrupts the liver's normal structure and function, ultimately leading to liver failure if left untreated. There are various causes of liver cirrhosis, including chronic alcohol abuse, viral hepatitis (such as hepatitis B and C), Non- Alcoholic Fatty Liver Disease (NAFLD), and autoimmune liver diseases [1,2].

The liver plays a crucial role in the body's metabolism, detoxification, and the production of important proteins. As cirrhosis advances, these functions become compromised, resulting in a range of symptoms and complications. Common symptoms of liver cirrhosis include fatigue, weakness, abdominal pain, jaundice (yellowing of the skin and eyes), swelling in the abdomen and legs (ascites), and easy bruising and bleeding due to reduced production of clotting factors [3,4].

Lupus, formally known as Systemic Lupus Erythematosus (SLE), is a chronic autoimmune disease. Autoimmune diseases occur when the body's immune system mistakenly attacks its own tissues and organs. In the case of lupus, the immune system becomes hyperactive and targets various parts of the body, leading to inflammation and damage. While lupus can affect multiple organ systems, it primarily impacts the skin, joints, kidneys, heart, lungs, brain, and blood cells. The exact cause of lupus is not fully understood, but it is believed to involve a combination of genetic, hormonal, environmental, and immunological factors. Symptoms of lupus can vary widely among individuals and may include fatigue, joint pain andswelling, skin rashes (especially the butterfly rash a cross the cheeks and nose), fever, and sensitivity to sunlight. In severe cases, lupus can lead to organ damage and failure [5,6].

The relationship between liver cirrhosis and lupus lies in the potential for lupus to affect the liver, leading to a condition known as lupus hepatitis or autoimmune hepatitis. Autoimmune hepatitis is characterized by inflammation of the liver tissue caused by the immune system mistakenly attacking liver cells. In some lupus patients, the immune system may target the liver, causing hepatitis. This can result in elevated liver enzyme levels in blood tests and liver-related symptoms, such as abdominal discomfort and jaundice. However, not all lupus patients will develop lupus hepatitis, and it is considered a rare complication of the disease.

Lupus hepatitis can present challenges in diagnosis and management, as it may mimic other forms of liver disease, such as viral hepatitis. Medical professionals often rely on a combination of clinical symptoms, blood tests, imaging, and liver biopsy to differentiate lupus hepatitis from other liver conditions [7,8].

The exact mechanisms that lead to lupus hepatitis are not fully elucidated, but several factors are believed to contribute. Immune Dysregulation in lupus, the immune system is dysregulated and produces antibodies against the body's own tissues. This immune dysregulation can extend to the liver, leading to inflammation and damage. Genetic predisposition Some individuals with lupus may have genetic factors that make them more susceptible to liver involvement. Specific genetic markers have been associated with an increased risk of autoimmune hepatitis in lupus patients. Environmental Triggers are environmental factors, such as viral infections or exposure to certain drugs, can trigger autoimmune responses in individuals with lupus. These triggers may exacerbate liver inflammation. Cross-Reactive Antibodies which target both lupus-related antigens and liver-specific antigens, may contribute to liver damage in lupus patients. This antibody cross-reactivity is an area of ongoing research. Some medications used to manage lupus, such as corticosteroids and immunosuppressive drugs, can have hepatotoxic (liver-damaging) effects. These medications may contribute to liver complications in lupus patients. Once diagnosed, lupus hepatitis is typically managed with a combination of medications and close monitoring [9,10].

Immunosuppressive medications, such as corticosteroids (e.g., prednisone) and azathioprine, are often prescribed to suppress the immune system's attack on the liver. Managing the underlying lupus is crucial. Medications like hydroxychloroquine, which modulate the immune system, may be used to control lupus symptoms and reduce the risk of flares. Patients with lupus hepatitis require regular follow-up appointments and blood tests to assess liver function and adjust treatment as needed. Lifestyle modifications, such as avoiding alcohol and maintaining a healthy diet, can help support liver health. In severe cases where cirrhosis and liver failure develop, liver transplantation may be necessary. This involves replacing the damaged liver with a healthy donor liver [11,12]. Liver cirrhosis and lupus are distinct medical conditions, they can be linked through the development of lupus hepatitis, which involves autoimmune inflammation of the liver in some lupus patients. The relationship between these conditions underscores the complexity of autoimmune diseases and the potential for multi-organ involvement. Early diagnosis, appropriate medical management, and regular monitoring are essential in addressing liver complications in individuals with lupus, ultimately improving their quality of life and prognosis. Moreover, ongoing research into the mechanisms underlying lupus hepatitis may provide valuable insights into autoimmune liver diseases and their treatment. [13,14].

References

1. Bajpai VK . Clonal multipotency and effect of long-term in vitro expansion on differentiation potential of human hair follicle derived mesenchymal stem cells. Stem Cell Res.2012; 8 (1):74-84.

   [Cross Ref][Google Scholar] [Pub Med] 

2. Chen TS. Adipose stem cells preincubated with theanine exert liver regeneration through increase of stem cell paracrine VEGF and suppression of ROS, pyroptosis as well as autophagy markers in liver damage induced by N-nitrosodiethylamine. Life Sci.2022; 308(1): 120969.

   [Cross Ref][Google Scholar]

3. Eliopoulos N. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice Blood.(2005); 106 (13): 4057–4065 .

   [Cross Ref][Google Scholar] [Pub Med] 

4.  Engelmann C. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism, and mitochondrial dysfunction. J. Hepatol.(2021);75(Suppl):S49-S66. 

   [Cross Ref][Google Scholar] [Pub Med] 

5. Gines P. Screening for liver fibrosis in the general population: a call for action Lancet Gastroenterol. Hepatol.(2016); 1(3):256-260.

   [Cross Ref][Google Scholar] [Pub Med] 

6. Ginès P. Liver cirrhosis. Lancet(2021) .

   [Cross Ref][Google Scholar] [Pub Med] 

7. Kang Y. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2/NQO-1 pathway. Free Radic. Biol. Med. (2022).

   [Cross Ref][Google Scholar] [Pub Med] 

8. Kojima Y. Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditions. Regen. Ther. (2019); 11:269-281.

   [Cross Ref][Google Scholar] [Pub Med]

9. Lee JM. Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. Int. Immunopharmacol.(2012);13(2):219-224.

   [Cross Ref] [Google Scholar] [Pub Med] 

10. Liu Z. Human umbilical cord mesenchymal stromal cells rescue mice from acetaminophen-induced acute liver failure. Cytotherapy (2014);16(9):1207-1219.

    [Cross Ref][Google Scholar] [Pub Med]

11.  Zhao Z. siRNA-and miRNA-based therapeutics for liver fibrosis. Transl. Res.(2019);214:17-29 .

    [Cross Ref] [Google Scholar] [Pub Med] 

12.  Albillos A . Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. (2014); 61(6):1385-1396.

    [Cross Ref][Google Scholar] [Pub Med]

13.  Lee UE .Mechanisms of hepatic fibrogenesis .Best Pract. Res. Clin. Gastroenterol.(2011);25(2):195-206.

    [Cross Ref] [Google Scholar] [Pub Med]

14.  Takehara T. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. (2004);127(4):1189-1197. 

    [Cross Ref][Google Scholar] [Pub Med]